Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

SAEs occurred in CORD I (two tendon ruptures and the complex regional pain syndrome), two occurred in JOINT II (DVT and a tendon rupture), one occurred in CORD II (a pulley ligament injury) and one tendon rupture occurred in the PK study.

"In summary, we believe that based on all clinical data for XIAFLEX in Dupuytren's contracture to date, we are positioned to bring a novel therapeutic to market that has the potential to revolutionize the treatment of Dupuytren's contracture," stated Mr. Anido. "The data indicate that approximately 4 out of 5 patients may achieve at least a 50% reduction in their contractures, and we believe the rate of reported serious adverse events compares favorably to the complications of surgery described in the available literature."

Conference Call

Auxilium will hold a conference call today, June 3, 2008 at 8:45 a.m. ET, to discuss the results of the CORD I and II studies and the PK study and provide updates on the XIAFLEX programs in general. The conference call will be simultaneously web cast on Auxilium's web site and archived for future review until July 3, 2008. Reference materials for the conference call also will be available on Auxilium's web site.

Conference call details:

Date: Tuesday, June 3, 2008

Time: 8:45 a.m. ET

Dial-in (U.S.): 800-322-2803

Dial-in (International): 617-614-4925

Password: 59892572

The reference materials that will be utilized by the Company during the

call may be accessed by clicking the "For Investors" tab on the home page

of the Company's web site at http://www. auxilium.com

Web cast: http://www.auxilium.com

To access an audio replay of the call:

Access number (U.S.): 888-286-8010

Access number (International): 617-801-6888

Conference ID#: 29592205

About Dupuytren's Contracture

D
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LigoCyte Pharmaceuticals, Inc. , a private, clinical-stage ... vaccine products, announced today that it has initiated ... (IM) norovirus vaccine candidate, marking the fourth human ... (VLP) vaccine program.  The Phase I dose-escalation study ...
... Top researchers at the Gastrointestinal Cancer Research Lab at ... clinical applications of BCM-95®, a new patented extract of ... Previous studies have shown that BCM-95 curcumin was 7-10 ... had a retention time in the bloodstream between 8 ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 2LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 3BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... has been effective for inoperable liver cancer. It is a year since ... a 25 ... rate in either reducing tumour size or the number of tumours. Till ... tumours, who cannot be treated by any other means. ,TheraSphere ...
... who suffer from dementia benefit from music therapy. The therapy ... The trials have found that the therapy is popular with ... at Imperial College London are planning to carry out a ... has long term benefits for dementia sufferers. If their results ...
... with low birth weight can significantly improve survival rates, ... diseases. The research involved 1,154 full-term but smaller than ... 5 1/2 pounds or less. Mothers fed them supplements ... the 20 who died had not been receiving zinc ...
... sole franchisee for US based Medicine Shoppe International, with operations ... from list of its target for operations in the country. ... to expand its franchisee operations from the present 19 outlets ... has decided to put on hold the commencing of operations ...
... a heavy breakfast and a steaming cup of tea may increase ... fried food each morning are at twice the risk of ... to reduce the incidence of cancer is to begin the day ... ,Cancer of the oesophagus - the food pipe connecting the stomach ...
... are more likely to get diagnosed with the progressive brain ... the case, although some have suggested that the disease may ... before it manifests itself elsewhere. ,Dr Robert Abbott, ... effectively identify people with early or suspected disease or people ...
Cached Medicine News:Health News:Cut down on fries 2